Project Grant K22CA303691
- The National Cancer Institute awarded The Research Foundation For The State University Of New York (operating as Stony Brook University) $566,281 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate epigenetic mechanisms underlying the more favorable prognosis of IDH-mutant gliomas compared to glioblastoma. The research examines how isocitrate dehydrogenase (IDH) mutations induce DNA hypermethylation that alters gene regulation and chromatin...
- The National Cancer Institute, under the Department of Health and Human Services, awarded The Research Foundation For The State University Of New York (operating as Stony Brook University) $498,775 under Cancer Biology Research (CFDA 93.396) on July 1, 2026. The award funds investigation of targetable mechanisms driving altered cell states in castration-resistant prostate cancer. The project dissects the emergence of a specific cellular subtype in early-stage prostate cancer capable of...
- The National Institute of General Medical Sciences awarded The Research Foundation For The State University Of New York (Stony Brook University) $432,569 on March 5, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate the regulatory mechanisms of extracellular particle-mediated intercellular signaling. The research deciphers how cells release extracellular particles containing biomolecules to establish non-contact communication with neighboring or...
- The National Cancer Institute awarded The Research Foundation For The State University Of New York (operating as Stony Brook University) $130,941 on December 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support biomedical training in cancer research. The award funds research on the role of apelin in skeletal muscle during cancer cachexia development and recovery. Cancer cachexia affects up to 80 percent of cancer patients and accounts for up to 20 percent of cancer...
- The National Institute of General Medical Sciences awarded The Research Foundation For The State University Of New York, operating as Stony Brook University, $432,892 on June 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support research into mycobacterial cell envelope organization and adaptation to environmental stress. The research program investigates how mycobacteria adapt their surface proteins, transport and modulate lipoproteins, and reorganize...
- The National Cancer Institute awarded The Trustees of Columbia University in the City of New York $681,818 on June 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct research into restoring anti-tumor immunity in chromosomally unstable tumors. The research addresses chromosomal instability (CIN)—frequent chromosome missegregation during mitosis—as a genomic hallmark of solid tumors that correlates with immune evasion and resistance to immunotherapies. The project...
- The National Cancer Institute awarded Weill Medical College of Cornell University $149,190 on January 14, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research decoding adaptive functions of the STING protein in cancer progression. The research investigates how STING, a stimulator of interferon genes, adopts context-dependent roles across different cellular signaling pathways—including innate immunity, endoplasmic reticulum stress response, and the NF-kappa-B...
- The National Institute of General Medical Sciences awarded The Research Foundation For The State University Of New York, operating as Stony Brook University, $429,262 on May 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support five years of research into germline ribosomal DNA maintenance mechanisms. The research investigates how eukaryotic cells maintain ribosomal DNA (rDNA) across generations despite the inherent instability of these repetitive...
- The National Institute of General Medical Sciences awarded $534,644 to Sloan-Kettering Institute for Cancer Research on June 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate the role of cohesin-STAG2 in R-loop homeostasis and its implications for cancer biology. The research dissects mechanisms underlying R-loop accumulation in STAG2-deficient cells, which frequently harbor mutations in cancer. The work will examine how loss of STAG2 (the most...
- The National Cancer Institute awarded The Research Foundation For The State University Of New York (operating as Stony Brook University) $532,553 under Project Grant R01CA315976 on July 1, 2026, to investigate temozolomide-induced DNA damage repair in glioblastoma cells, with particular focus on how transcription-coupled nucleotide excision repair (TC-NER) pathways resolve alkylation damage and contribute to drug resistance. The research examines how temozolomide adducts arrest RNA polymerase II...
The National Cancer Institute awarded The Research Foundation For The State University Of New York (operating as Stony Brook University) $223,938 on September 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support basic research on the mechanisms of cGAS activation in innate immune response to cytosolic double-stranded DNA. The research elucidates how MRE11, a DNA repair protein, mediates cGAS release from chromatin and facilitates cGAS-STING pathway activation in response to oncogene-induced DNA damage. The study comprises three aims: Aim 1 investigates how specific histone modifications (H3K79ME2 and H3K27AC) influence cGAS release from chromatin through MRE11 interactions using histone methylation inhibitors, siRNA, CRISPR/Cas9-based gene knockdown, chromatin immunoprecipitation assays, and in vitro nucleosome binding experiments. Aim 2 explores whether additional regulatory steps beyond cytoplasmic translocation and dsDNA sensing are required for full cGAS activation, employing R255A mutants and cGAS variants with nuclear localization or export signals. Aim 3 involves creating stable cell lines expressing BioID2-tagged cGAS and MRE11 for proximity-labeling proteomics to identify interacting proteins that clarify MRE11-mediated cGAS activation mechanisms. Performance occurs in Stony Brook, New York from September 1, 2026 through August 31, 2029. Stony Brook University operates as a child entity under The Research Foundation For The State University Of New York parent, which serves as the centralized research administration and sponsored-programs office for the SUNY system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $223.9k | 8/31/26 |